Evaluation and modifcation of lung immune prognostic index in patients with metastatic NSCLC treated by immunotherapy

Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).

Material and methods. Baseline neutrophil-to-lymphocyte ratio, lactate dehydrogenase, hemoglobin, platelets, and fibrinogen level were collected from 133 patients treated with ICI in monotherapy or combination between July 2015 and July 2022 in N.N. Blokhin NMRCO. According to evaluating factors patients were divided into three groups of “good” (LIPI 0/mLIPI 0–1), “intermediate” (LIPI 1/mLIPI 2–3) and “poor” prognosis (LIPI 2/mLIPI 4–5). The primary endpoint was progression free survival (PFS).

Results. The median PFS for the LIPI groups were 9.7 months (1.4–17.9; 95 % CI), 7.9 months (5.9–9.9; CI 95 %) and 6.0 months (4.07–7.93; 95 % CI) in the “good”, “intermediate” and “poor” prognosis groups, respectively; the hazard ratio (HR) for patients in the “poor” prognosis group (17 patients) was 2.02 (1.06–3.84; 95 % CI) compared with the “good” LIPI group (p=0.03). The median PFS for mLIPI groups were 9.0 months (4.53–13.47; 95 % CI), 8.0 months (5.4–10.6; CI 95 %) and 2.0 months. (1.33–2.67; 95 % CI) in the “good”, “intermediate” and “poor” prognosis groups, respectively. The HR for patients in the “poor” prognosis group (n=12) was 3.12 (1.51–6.46; 95 % CI) compared with the “good” mLIPI group (p=0.002).

Conclusion. Baseline LIPI and mLIPI predicts potential resistance to ICI treatment in mNSCLC patients. 

1. Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M., Poddubskaya E., Borghaei H., Felip E., Paz-Ares L., Pluzanski A., Reckamp K.L., Burgio M.A., Kohlhäeuf M., Waterhouse D., Barlesi F., Antonia S., Arrieta O., Fayette J., Crinò L., Rizvi N., Reck M., Hellmann M.D., Geese W.J., Li A., Blackwood-Chirchir A., Healey D., Brahmer J., Eberhardt W.E.E. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35): 3924–33. doi: 10.1200/JCO.2017.74.3062.

2. Antonia S.J., Borghaei H., Ramalingam S.S., Horn L., De Castro Carpeño J., Pluzanski A., Burgio M.A., Garassino M., Chow L.Q.M., Gettinger S., Crinò L., Planchard D., Butts C., Drilon A., Wojcik-Tomaszewska J., Otterson G.A., Agrawal S., Li A., Penrod J.R., Brahmer J. Fouryear survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019; 20(10): 1395–1408. doi: 10.1016/S1470-2045(19)30407-3.

3. Herbst R.S., Baas P., Kim D.W., Felip E., Pérez-Gracia J.L., Han J.Y., Molina J., Kim J.H., Arvis C.D., Ahn M.J., Majem M., Fidler M.J., de Castro G. Jr., Garrido M., Lubiniecki G.M., Shentu Y., Im E., DolledFilhart M., Garon E.B. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540–50. doi: 10.1016/S0140-6736(15)01281-7.

4. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., Gadgeel S.M., Hida T., Kowalski D.M., Dols M.C., Cortinovis D.L., Leach J., Polikoff J., Barrios C., Kabbinavar F., Frontera O.A., De Marinis F., Turna H., Lee J.S., Ballinger M., Kowanetz M., He P., Chen D.S., Sandler A., Gandara D.R.; OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–65. doi: 10.1016/S0140-6736-(16)32517-X. Erratum in: Lancet. 2017; 389(10077): e5.

5. Reck M., Rodríguez-Abreu D., Robinson A.G., Hui R., Csőszi T., Fülöp A., Gottfried M., Peled N., Tafreshi A., Cuffe S., O’Brien M., Rao S., Hotta K., Leal T.A., Riess J.W., Jensen E., Zhao B., Pietanza M.C., Brahmer J.R. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021; 39(21): 2339–49. doi: 10.1200/JCO.21.00174.

6. Garon E.B., Hellmann M.D., Rizvi N.A., Carcereny E., Leighl N.B., Ahn M.J., Eder J.P., Balmanoukian A.S., Aggarwal C., Horn L., Patnaik A., Gubens M., Ramalingam S.S., Felip E., Goldman J.W., Scalzo C., Jensen E., Kush D.A., Hui R. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019; 37(28): 2518–27. doi: 10.1200/JCO.19.00934.

7. Herbst R.S., Giaccone G., de Marinis F., Reinmuth N., Vergnenegre A., Barrios C.H., Morise M., Felip E., Andric Z., Geater S., Özgüroğlu M., Zou W., Sandler A., Enquist I., Komatsubara K., Deng Y., Kuriki H., Wen X., McCleland M., Mocci S., Jassem J., Spigel D.R. Atezolizumab for FirstLine Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14): 1328–39. doi: 10.1056/NEJMoa1917346.

8. Lin A., Wei T., Meng H., Luo P., Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer. 2019; 18(1): 139. doi: 10.1186/s12943-019-1062-7.

9. Hellmann M.D., Ciuleanu T.E., Pluzanski A., Lee J.S., Otterson G.A., Audigier-Valette C., Minenza E., Linardou H., Burgers S., Salman P., Borghaei H., Ramalingam S.S., Brahmer J., Reck M., O’Byrne K.J., Geese W.J., Green G., Chang H., Szustakowski J., Bhagavatheeswaran P., Healey D., Fu Y., Nathan F., Paz-Ares L. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22): 2093–2104. doi: 10.1056/NEJMoa1801946.

10. Vanderwalde A., Spetzler D., Xiao N., Gatalica Z., Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018; 7(3): 746–56. doi: 10.1002/cam4.1372. Erratum in: Cancer Med. 2018; 7(6): 2792.

11. Socinski M.A., Jotte R.M., Cappuzzo F., Nishio M., Mok T.S., Reck M., Finley G., Yu W., Patel H. Paranthaman N., Bara I., West H. Pooled analyses of immune-related adverse events (irAEs) and efcacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. J Clin Oncol. 2021; 39(Suppl_15). doi: 10.1200/JCO.2021.39.15_suppl.9002.

12. Wang Z., Zhan P., Lv Y., Shen K., Wei Y., Liu H., Song Y. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res. 2019; 8(3): 214–26. doi: 10.21037/tlcr.2019.06.10.

13. Tong T., Guan Y., Xiong H., Wang L., Pang J. A Meta-Analysis of Glasgow Prognostic Score and Modifed Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma. Front Oncol. 2020; 10. doi: 10.3389/fonc.2020.01541.

14. Banna G.L., Cortellini A., Cortinovis D.L., Tiseo M., Aerts J.G.J.V., Barbieri F., Giusti R., Bria E., Grossi F., Pizzutilo P., Berardi R., Mora bito A., Genova C., Mazzoni F., Di Noia V., Signorelli D., Gelibter A., Macerelli M., Rastelli F., Chiari R., Rocco D., Gori S., De Tursi M., Di Marino P., Mansueto G., Zoratto F., Filetti M., Montrone M., Citarella F., Marco R., Cantini L., Nigro O., D’Argento E., Buti S., Minuti G., Landi L., Guaitoli G., Lo Russo G., De Toma A., Donisi C., Friedlaender A., De Giglio A., Metro G., Porzio G., Ficorella C., Addeo A. The lung immuno-oncology prognostic score (LIPS-3): a prognostic classifcation of patients receiving frst-line pembrolizumab for PD-L1 ≥ 50 % advanced non-small-cell lung cancer. ESMO Open. 2021; 6(2). doi: 10.1016/j.esmoop.2021.100078. Erratum in: ESMO Open. 2021; 6(3).

15. Lenci E., Cantini L., Pecci F., Cognigni V., Agostinelli V., Mentrasti G., Lupi A., Ranallo N., Paoloni F., Rinaldi S., Nicolardi L., Caglio A., Aerts S., Cortellini A., Ficorella C., Chiari R., Di Maio M., Dingemans A.C., Aerts J.G.J.V., Berardi R. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with FirstLine Pembrolizumab. J Clin Med. 2021; 10(5): 1005. doi: 10.3390/jcm10051005.

16. Mezquita L., Auclin E., Ferrara R., Charrier M., Remon J., Planchard D., Ponce S., Ares L.P., Leroy L., Audigier-Valette C., Felip E., Zerón-Medina J., Garrido P., Brosseau S., Zalcman G., Mazieres J., Caramela C., Lahmar J., Adam J., Chaput N., Soria J.C., Besse B. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3): 351–7. doi: 10.1001/jamaoncol.2017.4771.

17. Meyers D.E., Stukalin I., Vallerand I.A., Lewinson R.T., Suo A., Dean M., North S., Pabani A., Cheng T., Heng D.Y.C., Bebb D.G., Morris D.G. The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers (Basel). 2019; 11(11): 1713. doi: 10.3390/cancers11111713.

18. Kazandjian D., Gong Y., Keegan P., Pazdur R., Blumenthal G.M. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer. JAMA Oncol. 2019; 5(10): 1481–5. doi: 10.1001/jamaoncol.2019.1747.

19. Ruiz-Bañobre J., Areses-Manrique M.C., Mosquera-Martínez J., Cortegoso A., Afonso-Afonso F.J., de Dios-Álvarez N., Fernández-Núñez N., Azpitarte-Raposeiras C., Amenedo M., Santomé L., Fírvida-Pérez J.L., García-Campelo R., García-González J., Casal-Rubio J., Vázquez S. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy. Transl Lung Cancer Res. 2019; 8(6): 1078–85. doi: 10.21037/tlcr.2019.11.07.

20. Sorich M.J., Rowland A., Karapetis C.S., Hopkins A.M. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. J Thorac Oncol. 2019; 14(8): 1440–6. doi: 10.1016/j.jtho.2019.04.006.

21. Benitez J.C., Recondo G., Rassy E., Mezquita L. The LIPI score and infammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Q J Nucl Med Mol Imaging. 2020; 64(2): 162–74. doi: 10.23736/S1824-4785.20.03250-1.

22. Huang L., Han H., Zhou L., Chen X., Xu Q., Xie J., Zhan P., Chen S., Lv T., Song Y. Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis. Front Oncol. 2021; 11. doi: 10.3389/fonc.2021.670230.

23. Chen C., Song Z., Wang W., Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Mol Clin Oncol. 2021; 14(3): 59. doi: 10.3892/mco.2021.2221.

24. Huang Y., Su C., Jiang H., Liu F., Yu Q., Zhou S. The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching. J Cancer. 2022; 13(1): 51–61. doi: 10.7150/jca.55159.

25. Yu D., Liu B., Zhang L., DU K. Platelet count predicts prognosis in operable non-small cell lung cancer. Exp Ther Med. 2013; 5(5): 1351–4. doi: 10.3892/etm.2013.1003.

26. Mitsui S., Tanaka Y., Doi T., Hokka D., Maniwa Y. Prognostic value of preoperative plasma fibrinogen levels in resected stage I non-small cell lung cancer. Thorac Cancer. 2022; 13(10): 1490–5. doi: 10.1111/1759-7714.14419.

27. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–47. doi: 10.1016/j.ejca.2008.10.026.

28. Xie J., Zang Y., Liu M., Peng L., Zhang H. The Lung Immune Prognostic Index May Predict the Efcacy of Diferent Treatments in Patients with Advanced NSCLC: A Meta-Analysis. Oncol Res Treat. 2021; 44(4): 164–75. doi: 10.1159/000514443.

29. Balkwill F.R., Mantovani A. Cancer-related infammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012; 22(1): 33–40. doi: 10.1016/j.semcancer.2011.12.005.

30. Greten F.R., Grivennikov S.I. Infammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1): 27–41. doi: 10.1016/j.immuni.2019.06.025.

31. Scilla K.A., Bentzen S.M., Lam V.K., Mohindra P., Nichols E.M., Vyfhuis M.A., Bhooshan N., Feigenberg S.J., Edelman M.J., Feliciano J.L. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. Oncologist. 2017; 22(6): 737–42. doi: 10.1634/theoncologist.2016-0443.

32. Takada K., Takamori S., Yoneshima Y., Tanaka K., Okamoto I., Shimokawa M., Oba T., Osoegawa A., Tagawa T., Takenoyama M., Oda Y., Nakanishi Y., Mori M. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer. 2020; 145: 18–26. doi: 10.1016/j.lungcan.2020.04.034.

33. Ding J., Karp J.E., Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017; 19(4): 353–63. doi: 10.3233/CBM-160336.

34. Liu R., Cao J., Gao X., Zhang J., Wang L., Wang B., Guo L., Hu X., Wang Z. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L. Tumour Biol. 2016; 37(10): 14083–8. doi: 10.1007/s13277-016-5228-2.